AU2003287006B2 - Preventing desensitization of receptors - Google Patents
Preventing desensitization of receptors Download PDFInfo
- Publication number
- AU2003287006B2 AU2003287006B2 AU2003287006A AU2003287006A AU2003287006B2 AU 2003287006 B2 AU2003287006 B2 AU 2003287006B2 AU 2003287006 A AU2003287006 A AU 2003287006A AU 2003287006 A AU2003287006 A AU 2003287006A AU 2003287006 B2 AU2003287006 B2 AU 2003287006B2
- Authority
- AU
- Australia
- Prior art keywords
- receptor
- disease
- patient
- heart
- pathological condition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000586 desensitisation Methods 0.000 title claims description 24
- 102000005962 receptors Human genes 0.000 claims description 69
- 108020003175 receptors Proteins 0.000 claims description 69
- 201000010099 disease Diseases 0.000 claims description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 43
- HYHSBSXUHZOYLX-WDSKDSINSA-N S-nitrosoglutathione Chemical group OC(=O)[C@@H](N)CCC(=O)N[C@@H](CSN=O)C(=O)NCC(O)=O HYHSBSXUHZOYLX-WDSKDSINSA-N 0.000 claims description 40
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 35
- 239000002840 nitric oxide donor Substances 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 24
- 230000001575 pathological effect Effects 0.000 claims description 22
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical group CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims description 18
- 229940039009 isoproterenol Drugs 0.000 claims description 17
- 239000000048 adrenergic agonist Substances 0.000 claims description 11
- 230000000747 cardiac effect Effects 0.000 claims description 10
- 238000001356 surgical procedure Methods 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 102000015433 Prostaglandin Receptors Human genes 0.000 claims description 6
- 108010050183 Prostaglandin Receptors Proteins 0.000 claims description 6
- 238000005086 pumping Methods 0.000 claims description 6
- 230000002861 ventricular Effects 0.000 claims description 6
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 5
- 230000009471 action Effects 0.000 claims description 5
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 5
- 208000037905 systemic hypertension Diseases 0.000 claims description 5
- 230000004217 heart function Effects 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- 230000004968 inflammatory condition Effects 0.000 claims description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 2
- 206010024119 Left ventricular failure Diseases 0.000 claims description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 2
- 206010039163 Right ventricular failure Diseases 0.000 claims description 2
- 208000026251 Opioid-Related disease Diseases 0.000 claims 1
- 108010001742 S-Nitrosoglutathione Proteins 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000005040 opiate dependence Diseases 0.000 claims 1
- ICRHORQIUXBEPA-UHFFFAOYSA-N thionitrous acid Chemical group SN=O ICRHORQIUXBEPA-UHFFFAOYSA-N 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 14
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 14
- 108091006027 G proteins Proteins 0.000 description 11
- 102000030782 GTP binding Human genes 0.000 description 11
- 108091000058 GTP-Binding Proteins 0.000 description 11
- 230000001276 controlling effect Effects 0.000 description 10
- 108091005682 Receptor kinases Proteins 0.000 description 8
- 208000000059 Dyspnea Diseases 0.000 description 7
- 206010013975 Dyspnoeas Diseases 0.000 description 7
- 239000000556 agonist Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 229940127240 opiate Drugs 0.000 description 7
- 108060003345 Adrenergic Receptor Proteins 0.000 description 6
- 102000017910 Adrenergic receptor Human genes 0.000 description 6
- 108010058846 Ovalbumin Proteins 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 210000004165 myocardium Anatomy 0.000 description 6
- 229940092253 ovalbumin Drugs 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 208000013220 shortness of breath Diseases 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 5
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010007558 Cardiac failure chronic Diseases 0.000 description 3
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 3
- QQZWEECEMNQSTG-UHFFFAOYSA-N Ethyl nitrite Chemical compound CCON=O QQZWEECEMNQSTG-UHFFFAOYSA-N 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229960001089 dobutamine Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 229960002329 methacholine Drugs 0.000 description 3
- 230000001235 sensitizing effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 150000004006 C-nitroso compounds Chemical group 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 239000004395 L-leucine Substances 0.000 description 2
- 150000004007 S-nitroso compounds Chemical group 0.000 description 2
- XOWVFANEOZMPKG-REOHCLBHSA-N S-nitroso-L-cysteine Chemical compound OC(=O)[C@@H](N)CSN=O XOWVFANEOZMPKG-REOHCLBHSA-N 0.000 description 2
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- -1 e.g. Proteins 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000024765 knee pain Diseases 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- QWPCKAAAWDCDCW-VKHMYHEASA-N (2s)-2-amino-4-nitrososulfanylbutanoic acid Chemical compound OC(=O)[C@@H](N)CCSN=O QWPCKAAAWDCDCW-VKHMYHEASA-N 0.000 description 1
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 1
- 208000012260 Accidental injury Diseases 0.000 description 1
- 206010003598 Atelectasis Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-Leucine Natural products CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 150000004008 N-nitroso compounds Chemical class 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 150000004009 O-nitroso compounds Chemical group 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
- 208000029464 Pulmonary infiltrates Diseases 0.000 description 1
- UOHAKHBEJRPHQZ-VKHMYHEASA-N S-nitroso-L-cysteinylglycine Chemical compound O=NSC[C@H](N)C(=O)NCC(O)=O UOHAKHBEJRPHQZ-VKHMYHEASA-N 0.000 description 1
- ZIIQCSMRQKCOCT-YFKPBYRVSA-N S-nitroso-N-acetyl-D-penicillamine Chemical compound CC(=O)N[C@@H](C(O)=O)C(C)(C)SN=O ZIIQCSMRQKCOCT-YFKPBYRVSA-N 0.000 description 1
- 108010093594 S-nitrosoalbumin Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000004046 hyporesponsiveness Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000004041 inotropic agent Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
- 229960004027 molsidomine Drugs 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/280,085 US6627602B2 (en) | 2001-11-13 | 2002-10-25 | Preventing desensitization of receptors |
| US10/280,085 | 2002-10-25 | ||
| PCT/US2003/029134 WO2004039313A2 (en) | 2002-10-25 | 2003-10-20 | Preventing desensitization of receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003287006A1 AU2003287006A1 (en) | 2004-05-25 |
| AU2003287006B2 true AU2003287006B2 (en) | 2010-03-18 |
Family
ID=32228743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003287006A Ceased AU2003287006B2 (en) | 2002-10-25 | 2003-10-20 | Preventing desensitization of receptors |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US6627602B2 (https=) |
| EP (1) | EP1567182A4 (https=) |
| JP (2) | JP4705783B2 (https=) |
| AU (1) | AU2003287006B2 (https=) |
| CA (1) | CA2503624A1 (https=) |
| WO (1) | WO2004039313A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6627738B2 (en) * | 1995-09-15 | 2003-09-30 | Duke University | No-modified hemoglobins and uses therefor |
| CA2425489C (en) * | 2000-10-16 | 2011-05-17 | Duke University | Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis |
| AU2002224466A1 (en) * | 2000-10-31 | 2002-05-15 | Duke University | Hypotension |
| US20040110691A1 (en) * | 2001-11-13 | 2004-06-10 | Stamler Jonathan S. | Thiol reactive agents as a therapeutic modality |
| US6627602B2 (en) * | 2001-11-13 | 2003-09-30 | Duke University | Preventing desensitization of receptors |
| GB0326047D0 (en) * | 2003-11-07 | 2003-12-10 | Univ Sheffield | Substance |
| ES2543836T3 (es) * | 2004-04-23 | 2015-08-24 | Northern Sydney Local Health District | Procedimientos y composiciones para el tratamiento de afecciones miocárdicas |
| ES2731298T3 (es) | 2005-05-27 | 2019-11-14 | Univ North Carolina Chapel Hill | Partículas de liberación de óxido nítrico para agentes terapéuticos de óxido nítrico y aplicaciones biomédicas |
| JP2008303145A (ja) * | 2005-09-22 | 2008-12-18 | Takeda Chem Ind Ltd | Ｇｒｋ阻害剤からなる強心薬 |
| FR2914554B1 (fr) * | 2007-04-05 | 2009-07-17 | Germitec Soc Par Actions Simpl | Procede de suivi de l'uitilisation d'un appareil medical. |
| WO2010042546A1 (en) | 2008-10-06 | 2010-04-15 | Indiana University Research And Technology Corporation | Methods and apparatus for active or passive assistance in the circulatory system |
| WO2011022652A1 (en) | 2009-08-21 | 2011-02-24 | Novan, Inc. | Topical gels |
| CA2771389C (en) | 2009-08-21 | 2019-04-09 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
| BR112012008508A2 (pt) * | 2009-10-13 | 2017-06-13 | Novan Inc | revestimento de sol-gel, substrato, método para produzir um revestimento de sol-gel |
| US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
| WO2012118829A2 (en) | 2011-02-28 | 2012-09-07 | Novan, Inc. | Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same |
| HUE052023T2 (hu) * | 2016-05-27 | 2021-04-28 | Ipsen Biopharm Ltd | Triptofánnal vagy tirozinnal stabilizált folyékony neurotoxin készítmény |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020128205A1 (en) * | 2001-01-11 | 2002-09-12 | Duke University Office Of Science And Technology | Inhibiting GS-FDH to modulate NO bioactivity |
| AU2002211222B2 (en) * | 2000-10-16 | 2006-02-09 | Duke University | Therapeutic use of aerosolized S-nitrosoglutathione in cystic fibrosis |
| AU2002313758B2 (en) * | 2001-11-13 | 2006-06-22 | Duke University | Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4476108A (en) * | 1981-01-16 | 1984-10-09 | Kessler Jack H | Bactericidal method |
| JPS63208525A (ja) * | 1987-02-25 | 1988-08-30 | Kikkoman Corp | 心不全治療剤 |
| WO1992010228A1 (en) * | 1990-12-05 | 1992-06-25 | The General Hospital Corporation | Devices for treating pulmonary vasoconstriction and asthma |
| US5380758A (en) * | 1991-03-29 | 1995-01-10 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
| US5385937A (en) * | 1991-04-10 | 1995-01-31 | Brigham & Women's Hospital | Nitrosation of homocysteine as a method for treating homocysteinemia |
| US5891459A (en) * | 1993-06-11 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
| US5728705A (en) * | 1993-10-04 | 1998-03-17 | The Trustees Of Columbia University In The City Of New York | Method of inducing vasorelaxation to treat pulmonary hypertension |
| US6063407A (en) * | 1995-02-16 | 2000-05-16 | The General Hospital Corporation | Treatment of vascular thrombosis and restenosis with inhaled nitric oxide |
| US5703073A (en) * | 1995-04-19 | 1997-12-30 | Nitromed, Inc. | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs |
| US5645839A (en) * | 1995-06-07 | 1997-07-08 | Trustees Of Boston University | Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis |
| US6197745B1 (en) * | 1995-09-15 | 2001-03-06 | Duke University | Methods for producing nitrosated hemoglobins and therapeutic uses therefor |
| US6294517B1 (en) | 1996-02-02 | 2001-09-25 | Nitromed, Inc. | Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use |
| US5985862A (en) * | 1996-05-02 | 1999-11-16 | G.D. Searle & Co. | Pharmaceutical compositions having steroid nitrate ester derivatives useful as anti-inflammatory drugs |
| US6057367A (en) * | 1996-08-30 | 2000-05-02 | Duke University | Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses |
| EP1015490B1 (en) * | 1997-02-06 | 2004-04-14 | Duke University | No-modified hemoglobins and uses therefor |
| WO1998043621A1 (en) * | 1997-03-31 | 1998-10-08 | The Children's Medical Center Corporation | Nitrosylation to inactivate apoptotic enzymes |
| WO1998052580A1 (en) * | 1997-05-21 | 1998-11-26 | Duke University | Treating asthma by preventing and/or accommodating for s-nitrosothiol breakdown |
| US6486206B1 (en) * | 1997-09-29 | 2002-11-26 | Cprx Inc. | Mechanical and pharmacologic therapies to treat cardiac arrest |
| WO1999018949A1 (en) * | 1997-10-15 | 1999-04-22 | Thomas Jefferson University | Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal |
| AU1770299A (en) | 1997-12-23 | 1999-07-19 | Nycomed Imaging As | Nitric oxide releasing chelating agents and their therapeutic use |
| US6007824A (en) * | 1998-07-09 | 1999-12-28 | Duckett; Melvin J. | Natural composition and method for the treatment of sexual dysfunction |
| EP1126838A4 (en) * | 1998-10-30 | 2005-02-16 | Nitromed Inc | NITROSIS AND NITROSYAL NON-STEROID ANTI-INFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE |
| US7045152B2 (en) * | 1999-09-08 | 2006-05-16 | Duke University | Treating pulmonary disorders with gaseous agent causing repletion of GSNO |
| US6314956B1 (en) * | 1999-09-08 | 2001-11-13 | Duke University | Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders |
| CA2410632A1 (en) * | 2000-06-22 | 2001-12-27 | David S. Garvey | Nitrosated and nitrosylated taxanes, compositions and methods of use |
| US6359182B1 (en) | 2000-10-26 | 2002-03-19 | Duke University | C-nitroso compounds and use thereof |
| US6489206B2 (en) * | 2001-03-22 | 2002-12-03 | United Microelectronics Corp. | Method for forming self-aligned local-halo metal-oxide-semiconductor device |
| US6627602B2 (en) * | 2001-11-13 | 2003-09-30 | Duke University | Preventing desensitization of receptors |
-
2002
- 2002-10-25 US US10/280,085 patent/US6627602B2/en not_active Expired - Lifetime
-
2003
- 2003-06-30 US US10/608,120 patent/US6964984B2/en not_active Expired - Fee Related
- 2003-10-20 AU AU2003287006A patent/AU2003287006B2/en not_active Ceased
- 2003-10-20 JP JP2004548325A patent/JP4705783B2/ja not_active Expired - Fee Related
- 2003-10-20 WO PCT/US2003/029134 patent/WO2004039313A2/en not_active Ceased
- 2003-10-20 EP EP03777526A patent/EP1567182A4/en not_active Withdrawn
- 2003-10-20 CA CA002503624A patent/CA2503624A1/en not_active Abandoned
-
2005
- 2005-11-15 US US11/274,047 patent/US20060100159A1/en not_active Abandoned
-
2010
- 2010-04-26 JP JP2010101547A patent/JP2010159307A/ja not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002211222B2 (en) * | 2000-10-16 | 2006-02-09 | Duke University | Therapeutic use of aerosolized S-nitrosoglutathione in cystic fibrosis |
| US20020128205A1 (en) * | 2001-01-11 | 2002-09-12 | Duke University Office Of Science And Technology | Inhibiting GS-FDH to modulate NO bioactivity |
| AU2002313758B2 (en) * | 2001-11-13 | 2006-06-22 | Duke University | Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2503624A1 (en) | 2004-05-13 |
| EP1567182A4 (en) | 2010-09-08 |
| US6627602B2 (en) | 2003-09-30 |
| US20030092633A1 (en) | 2003-05-15 |
| JP2006503901A (ja) | 2006-02-02 |
| WO2004039313A2 (en) | 2004-05-13 |
| JP2010159307A (ja) | 2010-07-22 |
| AU2003287006A1 (en) | 2004-05-25 |
| JP4705783B2 (ja) | 2011-06-22 |
| WO2004039313A3 (en) | 2004-07-22 |
| EP1567182A2 (en) | 2005-08-31 |
| US20040053852A1 (en) | 2004-03-18 |
| US20060100159A1 (en) | 2006-05-11 |
| US6964984B2 (en) | 2005-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003287006B2 (en) | Preventing desensitization of receptors | |
| Khan et al. | Alpha‐2 and imidazoline receptor agonistsTheir pharmacology and therapeutic role | |
| Kamibayashi et al. | Clinical uses of α2-adrenergic agonists | |
| US6562855B1 (en) | Anaesthetic formulation comprising an NMDA-antagoinst and an alpha-2 adrenergic agonist | |
| Krolikowski et al. | Role of Erk1/2, p70s6K, and eNOS in isofluraneinduced cardioprotection during early reperfusion in vivo | |
| AU756136B2 (en) | Microdose therapy | |
| Valverde et al. | Alternatives to opioid analgesia in small animal anesthesia: alpha-2 agonists | |
| Katovich et al. | Angiotensin-(1-7) as an antihypertensive, antifibrotic target | |
| Hopster et al. | Pharmacology of the equine foot: medical pain management for laminitis | |
| Mendelson et al. | Are the toxicities of pentobarbital and ethanol mediated by the GABA-benzodiazepine receptor-chloride ionophore complex? | |
| WO2007057508A2 (en) | Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol | |
| AU2008348717B2 (en) | Novel composition for treating the side effects of anticancer treatments | |
| NZ249197A (en) | Use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine in the preparation of medicaments for the treatment or prophylaxis of pain and/or oedema | |
| Sharma et al. | Clonidine a wonder drug | |
| US7226766B2 (en) | S-methylcysteine, S-ethylcysteine, and related S-alkylthiols as antagonists to the effects of S-nitrosothiols and nitric oxide | |
| Ahmad et al. | Dexmedetomidine: Systemic effects and clinical application in animals | |
| Goudas | Clonidine | |
| Jaakola | Intra-operative use of alpha2-adrenoceptor agonists | |
| DK2766003T3 (en) | Composition for the prevention of neuropathic pain | |
| WO2023150572A1 (en) | Methods for reducing alcohol, drug, and food intake | |
| WO2002011729A1 (en) | Novel compositions and methods for treatment of male erectile dysfunction | |
| JPH08508710A (ja) | 新規処置方法 | |
| Ramzy | Endothelial Injury In Cardiac Transplantation: The Role Of Endothelin Antagonism And Protein Kinases | |
| MXPA99011610A (en) | Microdose therapy | |
| HK1028728B (en) | Microdose therapy of vascular conditions by no donors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |